Intellia Therapeutics to Report Topline Phase 3 Data from First In Vivo CRISPR Gene Editing Trial in Hereditary Angioedema on April 27

What's happening

Intellia Therapeutics announced on April 24, 2026, that it will report topline results from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) on April 27, 2026, during a webcast scheduled for 8:00 a.m. ET. The investigational therapy represents an in vivo CRISPR-based gene editing treatment for hereditary angioedema (HAE).

This announcement marks a historic milestone as the first Phase 3 data readout for any in vivo CRISPR gene editing therapy. The company's stock exhibited significant volatility following the news, closing down 14.11% at $13.63 on April 24 but recovering with a 19.27% surge in after-hours trading to $16.26.

Why it matters for markets

The Phase 3 data represents a pivotal moment for the $1.61 billion market cap company, with analyst consensus price targets of $19.52 implying 43.2% upside from the April 24 closing price of $13.63. NTLA has delivered strong performance with year-to-date returns of 51.61% and one-year returns of 66.63%, positioning the stock for potential significant movement based on trial outcomes.

Trading volume reached 5,464,472 shares on April 24, representing 1.67 times the 20-day average, indicating heightened investor interest ahead of the data release. The company's announcement coincided with a $400 million at-the-market common stock offering prospectus supplement, providing additional financial flexibility as it approaches this critical milestone.

As the first in vivo CRISPR therapy to reach Phase 3 readout, successful results could validate the entire gene editing sector's commercial potential, while disappointing data could raise questions about the technology's near-term viability for treating genetic diseases.

Sectors and assets to watch

The gene editing and CRISPR technology sector faces a defining moment with Intellia's data release, as the company operates as a clinical-stage biotech with $67.7 million in revenue and 377 employees. Beyond lonvoguran ziclumeran, Intellia's pipeline includes NTLA-2001 for transthyretin amyloidosis, also in Phase 3 trials, making the company a key bellwether for in vivo gene editing approaches.

Broader biotech sector participants developing competing gene editing platforms and rare disease therapies will likely experience secondary effects from Intellia's results, particularly companies focused on hereditary angioedema treatments and CRISPR-based therapeutic approaches.

What to watch next

Monitor NTLA's April 27, 2026, 8:00 a.m. ET webcast for topline efficacy and safety data from the Phase 3 HAELO trial, with particular attention to primary endpoint achievement and patient response rates. Post-data trading volume and price action will indicate market reception of the first-ever Phase 3 in vivo CRISPR results, potentially setting precedent for the gene editing sector's commercial trajectory.